Cargando…
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
PURPOSE: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior sy...
Autores principales: | Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel H., Vogel, Arndt, Edeline, Julien, Cattan, Stephane, Kudo, Masatoshi, Cheng, Ann-Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen L., Knox, Jennifer J., Qin, Shukui, Siegel, Abby B., Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard S., Zhu, Andrew X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784157/ https://www.ncbi.nlm.nih.gov/pubmed/35421228 http://dx.doi.org/10.1158/1078-0432.CCR-21-3807 |
Ejemplares similares
-
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
por: Merle, Philippe, et al.
Publicado: (2023) -
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240
por: Vogel, Arndt, et al.
Publicado: (2021) -
Keynotes
Publicado: (2023) -
Keynote Address
por: Zinsou, Lionel
Publicado: (2019) -
Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)